2026-10-14T04:06:46Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33870202 2026-09-17T03:40:04Z category_21 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_From mutation detection to treatment decisions: CRISPR-enabled diagnostics for drug-resistant tuberculosis.pdf Weijia Yi (24641523) Fukang Luo (14500750) Dianping Yi (25000690) Jing Guo (102972) Shan Liu (193759) Qibing Yan (25000693) Hongzhi Luo (12325703) Biotechnology antimicrobial resistance clinical translation CRISPR diagnostics drug-resistant tuberculosis heteroresistance mutation-to-drug interpretation <p>Effective management of drug-resistant tuberculosis requires molecular assays that not only detect Mycobacterium tuberculosis but also identify resistance-associated variants, support drug-level interpretation, and indicate when broader confirmatory testing is needed. This narrative review applies a mutation-to-drug-to-decision framework to distinguish assay validity, exact-variant detection, drug-level inference, and decision impact. We synthesize evidence on target accessibility, minority-allele preservation, multiplexing, direct-specimen testing, and sequencing enrichment, emphasizing how these factors shape clinical interpretability. Current evidence remains dominated by analytical studies, isolate-based evaluations, and small direct-specimen investigations, with prospective multicenter treatment-impact validation still lacking. Population-level benchmarks indicate incomplete biological coverage for compact target regions, reaching approximately 92.6% for rpoB RRDR-based rifampicin detection, 85.4% for katG codon 315 plus the inhA promoter for isoniazid, and 84.7%–88.2% for gyrA/gyrB-based fluoroquinolone detection. Allele-specific CRISPR is therefore best suited to rapid rule-in of selected resistance-associated variants, while dispersed or heterogeneous mechanisms require broader molecular or phenotypic assessment. CRISPR should complement WHO-recommended rapid molecular testing and targeted next-generation sequencing rather than replace established molecular or phenotypic methods.</p> 2026-09-17T03:40:04Z Dataset Dataset 10.3389/fbioe.2026.1947704.s001 https://figshare.com/articles/dataset/Data_Sheet_1_From_mutation_detection_to_treatment_decisions_CRISPR-enabled_diagnostics_for_drug-resistant_tuberculosis_pdf/33870202 CC BY 4.0